Skip to main content
Top
Published in: Cardiovascular Drugs and Therapy 2/2018

Open Access 01-04-2018 | ORIGINAL ARTICLE

Effect of Antazoline on Electrophysiological Properties of Atrial Muscle and Conduction System of the Heart

Authors: Bartłomiej Jacek Bińkowski, Marcin Makowski, Paweł Kubiński, Andrzej Lubiński

Published in: Cardiovascular Drugs and Therapy | Issue 2/2018

Login to get access

Abstract

Purpose

Antazoline is a first-generation antihistaminic agent with additional anticholinergic properties and antiarrhythmic potential. Recent data shows its high effectiveness in sinus rhythm restoration among patients with paroxysmal atrial fibrillation. The effect of antazoline on electrophysiological parameters of the heart in vivo has not yet been examined. The aim of this study was to evaluate changes in electrophysiological parameters of the heart muscle and conduction system as a response to increasing doses of antazoline.

Methods

After successful ablation of supraventricular arrhythmias, the electrophysiological parameters: sinus rhythm cycle length (SRCL), AH, HV, QRS, QT, QTc intervals, Wenckebach point (WP), sinus node recovery period (SNRT), intra- (hRA-CSos) and interatrial conduction time (hRA-CSd), right and left atrium refractory period (RA-; LA-ERP), and atrioventricular node refractory period (AVN-ERP) were assessed initially and after 100, 200, and 300 mg of antazoline given intravenously.

Results

Fifteen patients (8 males, 19–72 years old) undergoing EPS and RF ablation were enrolled. After 100 mg bolus, a significant reduction in SRCL was noticed. After antazoline administration, significant prolongation of HV, QRS, QTc, hRA-CSos, hRA-CSd intervals, RA– and LA-ERP and reduction of SRCL were observed. After a total dose of 300 mg, QT interval prolonged significantly. Increasing the dose of antazoline had no impact on AH, Wenckebach point, AVN-ERP, and SNRT.

Conclusion

Antazoline has an effect on electrophysiological parameters of the atrial muscle and has rapid onset of action. No negative effect on sinus node function and atrioventricular conduction in a unique property among antiarrhythmic drugs.
Literature
1.
go back to reference Heinberg CJ. A new synthetic anti-histaminic substance, antistine. Eye Ear Nose Throat Mon. 1947;26:639–41.PubMed Heinberg CJ. A new synthetic anti-histaminic substance, antistine. Eye Ear Nose Throat Mon. 1947;26:639–41.PubMed
2.
go back to reference McKechnie JK. The cardiac action of the antihistamine compounds. S Afr Med J. 1952;26:609–13.PubMed McKechnie JK. The cardiac action of the antihistamine compounds. S Afr Med J. 1952;26:609–13.PubMed
3.
go back to reference Angelakos ET. Influence of pharmacological agents on spontaneous and surgically induced hypothermic ventricular fibrillation. Ann N Y Acad Sci. 1959;80:351–64.CrossRefPubMed Angelakos ET. Influence of pharmacological agents on spontaneous and surgically induced hypothermic ventricular fibrillation. Ann N Y Acad Sci. 1959;80:351–64.CrossRefPubMed
4.
go back to reference Angelakos ET, Hegnauer AH. Pharmacological agents for the control of spontaneous ventricular fibrillation under progressive hypothermia. J Pharmacol Exp Ther. 1959;127:137–45.PubMed Angelakos ET, Hegnauer AH. Pharmacological agents for the control of spontaneous ventricular fibrillation under progressive hypothermia. J Pharmacol Exp Ther. 1959;127:137–45.PubMed
5.
go back to reference Kline SR, Dreifus LS, Watanabe Y, et al. Evaluation of the antiarrhythmic properties of antazoline. A preliminary study. Am J Cardiol. 1962;9:564–7.CrossRefPubMed Kline SR, Dreifus LS, Watanabe Y, et al. Evaluation of the antiarrhythmic properties of antazoline. A preliminary study. Am J Cardiol. 1962;9:564–7.CrossRefPubMed
6.
go back to reference Dreifus LS, McGarry TF, Watanabe Y. Clinical and physiological effect of antazoline, a new antiarrhythmic agent. American Heart Journal. 1963;65:607–14.CrossRef Dreifus LS, McGarry TF, Watanabe Y. Clinical and physiological effect of antazoline, a new antiarrhythmic agent. American Heart Journal. 1963;65:607–14.CrossRef
8.
go back to reference Reynolds EW Jr, Baird WM, Clifford ME. A clinical trial of antazoline in the treatment of arrhythmias. Am J Cardiol. 1964;14:513–21.CrossRefPubMed Reynolds EW Jr, Baird WM, Clifford ME. A clinical trial of antazoline in the treatment of arrhythmias. Am J Cardiol. 1964;14:513–21.CrossRefPubMed
9.
go back to reference Leon-Sotomayor L. A clinical evaluation of the antiarrhythmic properties of antazoline. Am J Cardiol. 1963;11:646–53.CrossRefPubMed Leon-Sotomayor L. A clinical evaluation of the antiarrhythmic properties of antazoline. Am J Cardiol. 1963;11:646–53.CrossRefPubMed
10.
go back to reference Lanng Nielsen J, Dahl R, Kissmeyer-Nielsen F. Immune thrombocytopenia due to antazoline (Antistina). Allergy. 1981;36:517–9.CrossRefPubMed Lanng Nielsen J, Dahl R, Kissmeyer-Nielsen F. Immune thrombocytopenia due to antazoline (Antistina). Allergy. 1981;36:517–9.CrossRefPubMed
11.
go back to reference Kuch M, Janiszewski M, Dluzniewski M, et al. Antazoline—ineffective or misprized in the treatment of paroxysmal atrial fibrillation? Pol J Cardiol. 2000;3:247–51. Kuch M, Janiszewski M, Dluzniewski M, et al. Antazoline—ineffective or misprized in the treatment of paroxysmal atrial fibrillation? Pol J Cardiol. 2000;3:247–51.
12.
go back to reference Piotrowski R, Krynski T, Baran J, et al. Antazoline for rapid termination of atrial fibrillation during ablation of accessory pathways. Cardiol J. 2014;21:299–303.CrossRefPubMed Piotrowski R, Krynski T, Baran J, et al. Antazoline for rapid termination of atrial fibrillation during ablation of accessory pathways. Cardiol J. 2014;21:299–303.CrossRefPubMed
13.
go back to reference Balsam P, Kozluk E, Peller M, et al. Antazoline for termination of atrial fibrillation during the procedure of pulmonary veins isolation. Adv Med Sci. 2015;60:231–5.CrossRefPubMed Balsam P, Kozluk E, Peller M, et al. Antazoline for termination of atrial fibrillation during the procedure of pulmonary veins isolation. Adv Med Sci. 2015;60:231–5.CrossRefPubMed
14.
go back to reference Farkowski MM, Maciąg A, Zurawska M, et al. Comparative effectiveness and safety of antazoline-based and propafenone-based strategies for pharmacological cardioversion of short-duration atrial fibrillation in the emergency department. Pol Arch Med Wewn. 2016;126:381–7.PubMed Farkowski MM, Maciąg A, Zurawska M, et al. Comparative effectiveness and safety of antazoline-based and propafenone-based strategies for pharmacological cardioversion of short-duration atrial fibrillation in the emergency department. Pol Arch Med Wewn. 2016;126:381–7.PubMed
15.
go back to reference Maciag A, Farkowski MM, Chwyczko T, et al. Efficacy and safety on antazoline in the rapid conversion of paroxysmal atrial fibrillation (the AnPAF study). Europace. 2017;19:1637–42.CrossRefPubMed Maciag A, Farkowski MM, Chwyczko T, et al. Efficacy and safety on antazoline in the rapid conversion of paroxysmal atrial fibrillation (the AnPAF study). Europace. 2017;19:1637–42.CrossRefPubMed
16.
go back to reference Piotrowski R, Giebultowicz J, Baran J et al. Antazoline-insights into drug-induced electrocardiographic and hemodynamic effects: Results of the ELEPHANT II substudy. Ann Noninvasive Electrocardiol 2017 25. Piotrowski R, Giebultowicz J, Baran J et al. Antazoline-insights into drug-induced electrocardiographic and hemodynamic effects: Results of the ELEPHANT II substudy. Ann Noninvasive Electrocardiol 2017 25.
17.
go back to reference Guerra F, Matassini MV, Scappini L, et al. Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis. Expert Rev Cardiovasc Ther. 2014;12:1067–75.CrossRefPubMed Guerra F, Matassini MV, Scappini L, et al. Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis. Expert Rev Cardiovasc Ther. 2014;12:1067–75.CrossRefPubMed
18.
go back to reference Camm AJ, Capucci A, Hohnloser SH, AVRO Investigators, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011;57:313–21.CrossRefPubMed Camm AJ, Capucci A, Hohnloser SH, AVRO Investigators, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011;57:313–21.CrossRefPubMed
Metadata
Title
Effect of Antazoline on Electrophysiological Properties of Atrial Muscle and Conduction System of the Heart
Authors
Bartłomiej Jacek Bińkowski
Marcin Makowski
Paweł Kubiński
Andrzej Lubiński
Publication date
01-04-2018
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 2/2018
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-018-6787-9

Other articles of this Issue 2/2018

Cardiovascular Drugs and Therapy 2/2018 Go to the issue